Increased transglomerular passage of plasma proteins as demonstrated by the presence of more than 0.5 g protein in 24-h urine is the diagnostic marker of clinical diabetic nephropathy. Preceding this stage, i.e. in the stage of incipient diabetic nephropathy, the urinary albumin excretion rate (UalbV) is slightly elevated (30-300 mg/24 h, Albustix negative), but these patients are at high risk for later development of clinical diabetic nephropathy [1] [2] [3] [4] . The pathophysiological basis for the slightly elevated urinary albumin escape seen in early diabetic renal disease has been debated intensively. It is usually ascribed to abnormalities located specifically in the kidneys -haemodynamic alterations [5, 6] and/or alterations in the properties of the glomerular filter [7, 8] . However, these changes might not be restricted to the kidneys. Indications of more generalized alterations in the transcapillary passage of small molecules [9] and of macromolecules [10] [11] [12] in patients with diabetic microangiopathy have been presented. In previous studies the transcapillary escape rate of albumin (TERalb) was found to be normal in short-term diabetic patients, but elevated in patients with clinical signs of microangiopathy or arterial hypertension [10] [11] [12] .
In the present study the TERalb was investigated in long-term Type 1 (insulin-dependent) diabetic patients with different levels of UalbV (normal range to overt diabetic nephropathy) as well as in normal controls.
The aim was to investigate whether a generally increased passage of albumin (i. e. TERaIb) is the result of diabetes duration alone or whether it is more specifically connected to the early or late development of diabetic nephropathy (i. e. the level of UalbV) in Type 1 patients.
Subjects and methods

Subjects
Seventy-five Type I patients with a diabetes duration of more than five years were studied. They had no history of non-diabetic renal or cardiac disease, and all had a negative bacterial culture of the urine. Fifteen healthy non-diabetic persons served as controls. All subjects gave their informed consent for participation, and the study was approved by the Regional Ethics Committee. The patients were subdivided into three groups according to the level of albuminuria identified on the basis of the median UalbV in three 24-h urine collections performed at home during normal physical activity. This was done in order to take into account the high (50%) day to day variation of the 24 h UalbV [13] . Normal controls delivered one 24-h urine. The three groups were defined as follows: Twelve months prior to the study these patients had entered a clinical trial of the effect on the UalbV of improved metabolic control using portable insulin pumps (CSII) versus conventional insulin treatment (CIT) as previously described [14] .
Group3:18
Typel patients with diabetic nephropathy (UalbV > 300 mg/24 h). Any ongoing antihypertensive treatment had been discontinued for 8 weeks except in two patients receiving diuretics due to mild oedema.
The clinical characteristics of patients and controls are shown in Table 1 . A close match of sex distribution, age and diabetes duration was obtained.
The patients in group I and 3 and the CIT group received conventional insulin treatment, i.e. 2-3 daily injections of intermediate -acting insulin often mixed with short-acting insulin.
Methods
The transcapillary escape rate of albumin was measured as described by Parring [15] . The investigations were carded out in the morning preceded by a normal breakfast and insulin injection at home• A canulla was inserted in the antecubital vein in each arm, and the patients had rested for 60 min in the supine position. 125I-human serum albumin (Code IFA-IT23S, Kjeller, Oslo, Norway) was used.
After intravenous injection of the tracer (2 lxCi) in one arm, 7 blood samples were collected from the other arm during the first hour. Plasma radioactivity was measured in each sample using a well-type scintillation detector and expressed as cpm/g total plasma protein. These ratios were plotted in semilogarithmic scale, and the transcapillary escape rate was calculated as the disappearance rate constant. Thus, the TER~tb is the fraction of the intravascular mass of albumin leaving the vascular bed per hour (%/h).
Plasma volume (PV, ml/1.73 m 2) was determined by retropolation of the disappearance curve to zero time and from the injected volume of tracer.
The glomerularfiltration rate (GFR) was measured with single intravenous injection of 51Cr EDTA, plotting the plasma disappearance of the tracer for 4 h [16]. The mean intraindividual coefficient of variation was 4.1%
Serum albumin (g/l) was measured using an ELISA assay [13] . The interassay variation was 8.3%. From these determinants the intravascular mass of albumin and the outflux of albumin per hour were calculated.
Intravascular mass of albumin (IVM) was calculated as plasma volume times s-albumin (g/1.73 m2).
Outflux of albumin was calculated as IVM times TER~Ib (g/h ×
m2).
The urinary albumin excretion was measured using an ELISA-assay [13] .
HbA1c was measured by a chromatographic technique [17] . The normal range was 4.1-6.4%.
S-creatinine was measured by a reaction rate kinetic principle eliminating pseudo-creatinines [18] . The interassay variation was 2.5%.
B-glucose was measured three times during the study using Hypocount (Suffolk, UK).
Statistical analysis
Results are given as mean + SD. The paired and unpaired Student's ttests were used for comparisons within and between groups. UalbV values were log-transformed before calculations. Significance levels were 0.05 (two-tailed).
Results
The TERalb was similar in normal controls and group I ~o (Fig. 1) . It was significantly higher in group 2 patients -~ with incipient nephropathy (p<0.01), and the mean O TERalb of group 2 and 3 was identical (Fig. 1) . There ,= was no significant correlation between TERal b and age ~= or TERalb and UalbV in any of the groups.
The blood pressure was higher and the GFR was lower in group 3 compared with the other three groups ( Table 1 ). The long-term metabolic control (HbA~) was worse in group3 compared with the other groups ~8 (Table 1) . B-glucose on the day of study was found to be significantly higher (p<0.01) in this group compared with group I (Table 2 ). However, in group 2 the 18 con-~, ventionally treated patients had similar metabolic con-"? trol, whereas the 18 insulin pump treated patients were in a significantly (p<0.01) better metabolic state (Tables I and 2 OOo= '~ll ~ trois, and even lower in group 3 (p< 0.05, Table 2 ). The plasma volume was similar in all groups, with a tendency to lower values in group2 (all 36 patients, p< 0.05) and, in consequence, the intravascular mass of albumin was significantly reduced in the groups with lower S-albumin ( Table 2 ). The outflux of albumin in group 3 was indistinguishable from normal controls and group I in spite of the elevated TERalb, because of the reduced intravascular mass of albumin.
Discussion
This study has shown that the TERalb is normal in longterm diabetic patients with normal UalbV. It has also shown that the TERalb is elevated to the same level in patients with microalbuminuria and in patients with overt clinical diabetic nephropathy. This observation corroborates the hypothesis that there may be a ceiling for the maximum rate of escape of albumin from the circulation [11] . Increased values of TERalb have been demonstrated previously in long-term diabetic patients with various degrees of microangiopathy and normal blood pressure [10] [11] [12] , and a normal TERalb has been found in short-term diabetic patients without microangiopathy [10, 11] . However, our observation of a bimodal distribution of the TERalb in long-term diabetic patients with Albustix negative urine, but different albuminuric levels, is new. The groups were well-matched according to sex, age and diabetes duration. The diabetes duration was as long or even longer than in previous studies of TER~b and long-term diabetes [10] [11] [12] . The TERalb is elevated in patients with arterial hypertension [11, 15] , and the blood pressure has been reported to be slightly elevated in diabetic patients with microalbuminuria [19] [20] [21] . However, before entrance into this study, group 2 patients with resting blood pressure higher than 160/95mmHg were excluded; therefore, the mean blood pressure was the same in group I and 2 and thus could not account for the elevated TER~bin the microalbuminuric group 2. Improved metabolic control reduces the TERa~b in poorly regulated short-term diabetic patients, insulin-dependent [22] as well as non-insulin-dependent [11] . Differences in metabolic control at the time of investigation could not explain the observed differences in TERalb in this study, because the metabolic control on the day of study was similar in group 1 and the insulin pump treated group 2 patients. Furthermore, the TERalb was unchanged during 12 months of strict metabolic control (data not shown). This is in contrast to what was found in short-term insulin-dependent diabetic patients [22] . Therefore, the metabolically independent elevation of TERalb seen in the microalbuminuric group 2 patients may be a marker of a more fundamental structural microvascular lesion, leading to the clinical manifestation of diabetic microangiopathy. The actual outflux of albumin from the vascular bed was higher in the microalbuminuric group 2 compared with normal controls and group I in spite of a decreased intravascular mass of albumin in group 2. In group 3 (diabetic nephropathy) an outflux of albumin was found indistinguishable from normal controls and group 1. This was due to a lower intravascular mass of albumin in these patients.
The reduced intravascular mass of albumin found in groups 2 and 3 will result in a decreased, intravascular colloid osmotic pressure which might lead to the oedema often found in patients with diabetic nephropathy. However, the interstitial colloid osmotic pressure was not measured in this study.
The significance of an increased outflux of proteins is unknown, but it might be an important mechanism in the development of diabetic microangiopathy [8, 23] . The coincident observation of microalbuminuria and increased TERalb may indicate that the structural and/ or haemodynamic abnormalities underlying the increased escape of albumin in the glomerular and extrarenal capillaries are the same. These abnormalities seem to be absent in long-term diabetic patients with normal UalbV, possibly explaining the almost normal life expectancy of Type 1 patients who do not develop proteinuria [24] . The structural abnormalities are probably different from what is classically described as diabetic microangiopathy, since in group 2 the increased UalbV and TER~b were observed in many patients, even before microaneurisms had appeared. Furthermore, the UalbV was found normal in many long-term diabetic patients, demonstrating glomerulosclerosis and increased thickness of the glomerular basement membrane [25] .
In conclusion, long-term diabetic patients with normal UalbV have normal TERalb values, whereas longterm diabetic patients with persistent microalbuminuria have an increased TER~b, independent of current metabolic control and blood pressure. These patients also demonstrate a decreased intravascular mass of albumin. Thus, microalbuminuria indicates profound alterations in Type 1 patients, and these alterations might be crucial in the development of lethal diabetic complications.
